The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607).
Kevin Kalinsky
No relevant relationships to disclose
Sandra J. Lee
No relevant relationships to disclose
Donald P. Lawrence
No relevant relationships to disclose
A. John Iafrate
No relevant relationships to disclose
Darrell R. Borger
Consultant or Advisory Role - Bio-Reference Laboratories; Licensee of SNaPshot genotyping platform
Bruce Jeffrey Averbook
No relevant relationships to disclose
Ahmad A. Tarhini
Consultant or Advisory Role - Genentech; MedImmune; Prometheus
Research Funding - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Prometheus
John M. Kirkwood
No relevant relationships to disclose